title: Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
abstract: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients.
  
  
  
  Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis.
  
  
  
  Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were ≥65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged <65 years and 97.7% (130/133) of those ≥65 years. Diabetes was the most common comorbidity in patients ≥65 years compared to younger patients (26.3% vs 12.4% P<.003). The most common adverse event (AE) in elderly patients was a grade 2 anaemia (35.3% vs 19.9% P<.004).
  
  
  
  Sofosbuvir/simeprevir plus a daily flat dose of RBV 800 mg for 12 weeks was highly effective and safe in genotype 1 elderly patients with compensated cirrhosis.
authors: Liver Disease Unit, Department of Liver Transplantation, San Camillo Forlanini Hospital, Rome, Italy.
authors: Adriano M
authors: AM
authors: Pellicelli
authors: Hepatology Department of Medicine, ASL Pescara, Pescara, Italy.
authors: Valeria
authors: V
authors: Pace Palitti
authors: Emergency Department, Galliera Hospital, Genoa, Italy.
authors: Pascal
authors: P
authors: Vignally
authors: Department of Experimental Medicine and Surgery, University of Tor Vergata, Rome, Italy.
authors: Francesca
authors: F
authors: Ceccherini-Silberstein
authors: Internal Medicine, Catholic University Policlinico Gemelli, Rome, Italy.
authors: Massimo
authors: M
authors: Siciliano
authors: Liver Disease Unit, Department of Liver Transplantation, San Camillo Forlanini Hospital, Rome, Italy.
authors: Valerio
authors: V
authors: Giannelli
authors: Gastroenterology, San Filippo Neri Hospital, Rome, Italy.
authors: Alessandra
authors: A
authors: Moretti
authors: Infectious Disease, ASL Teramo, Teramo, Italy.
authors: Pierluigi
authors: P
authors: Tarquini
authors: Infectious Disease, Umberto I Hospital, Siracusa, Italy.
authors: Gaetano
authors: G
authors: Scifo
authors: Infectious Disease, Sant'Anna and San Sebastiano Hospital Caserta, Rome, Italy.
authors: Vincenzo
authors: V
authors: Messina
authors: Center for Liver Disease, Fatebenefratelli Hospital, Napoli, Italy.
authors: Antonio
authors: A
authors: Ascione
authors: Infectious Disease, Cotugno Hospital, Napoli, Italy.
authors: Antonio
authors: A
authors: Izzi
authors: Digestive and Liver Disease Unit, Faculty Medicine and Psychology, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy.
authors: Massimo
authors: M
authors: Marignani
authors: Liver Disease Unit, Department of Liver Transplantation, San Camillo Forlanini Hospital, Rome, Italy.
authors: Cecilia
authors: C
authors: D'Ambrosio
authors: Liver Disease Unit, Department of Liver Transplantation, San Camillo Forlanini Hospital, Rome, Italy.
authors: Lucia
authors: L
authors: Fondacaro
authors: Division of General Surgery and Liver Transplantation, S. Camillo Forlanini Hospital, Rome, Italy.
authors: Giuseppe M
authors: GM
authors: Ettorre
authors: Radiology, Camillo Forlanini Hospital, Rome, Italy.
authors: Pasquale
authors: P
authors: Ialongo
authors: Liver Unit, Azienda Universitaria Pisana, Pisa, Italy.
authors: Rodolfo
authors: R
authors: Sacco
authors: Department of Experimental Medicine and Surgery, University of Tor Vergata, Rome, Italy.
authors: Carlo F
authors: CF
authors: Perno
authors: Infectious Disease, IRCCS San Matteo, Pavia, Italy.
authors: Giorgio
authors: G
authors: Barbarini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000209:etiology; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007558:Italy; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000821:virology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects; D000069616:Simeprevir / Q000008:administration & dosage* / Q000009:adverse effects; D000069474:Sofosbuvir / Q000008:administration & dosage* / Q000009:adverse effects; D000072230:Sustained Virologic Response
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D000069616:Simeprevir; D000069474:Sofosbuvir
keywords: cirrhosis; elderly; genotype 1; hepatitis C; simeprevir; sofosbuvir